Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| SanDisk | SK Hynix | Tempus AI | |
|---|---|---|---|
| Moat rating | narrow Narrow rather than wide: the FY2025 10-K Competition section opens 'Our industry is highly competitive' and names five vertically integrated flash rivals (Kioxia, Micron, Samsung, SK Hynix, Yangtze Memory), while Item 1A concedes SanDisk's products 'are designed to be largely interchangeable with competitors' products' in a market 'often subject to declining average selling prices'. It is not 'none', because the same filing discloses a genuinely durable consumer franchise and roughly 7,900 granted patents. | narrow SK hynix held ~62% of the AI-critical HBM market in Q2 2025 (Counterpoint, via TweakTown) and was first to mass-produce HBM4, but memory remains a cyclical three-player business where Samsung and Micron are closing the HBM gap — a real but contestable edge. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| Moat type | intangibles ip The only hard-to-replicate assets the filing actually claims are intangible: it reports 'a strong position in the Consumer end market' with 'significant consumer brands and franchises globally, with valuable patent portfolios containing approximately 7,900 granted patents and approximately 3,200 pending patent applications worldwide', and adds that non-patented IP, 'particularly some of our process technology, is an important factor in our success'. Cost-scale is the wrong label because the manufacturing scale sits in Flash Ventures, a 49.9%-owned JV co-owned with Kioxia, not in a proprietary fab base. | intangibles ip The advantage is process-and-packaging technology leadership: SK hynix achieved industry-first HBM4 mass production in September 2025 and has positioned itself as NVIDIA's key HBM partner, per its record FY2025 results. | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| Leadership | at parity At parity, not ahead: the 10-K Competition section positions SanDisk against vertically integrated suppliers Kioxia, Micron, Samsung, SK Hynix and Yangtze Memory, and Item 1A concedes its products are 'designed to be largely interchangeable with competitors' products'. Its explicit leadership claims are brand- and consumer-scoped ('industry leading consumer brand awareness and global retail distribution presence'), not technology- or share-scoped. | clear leader Clear leader in HBM (#1 at ~62% share, Q2 2025) and became the world's top overall memory supplier in Q2 2025; caveat: it sits #2 to Samsung in commodity DRAM by volume and Micron/Samsung are narrowing the HBM gap heading into HBM4. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| Pricing power | weak A price taker. The 10-K describes an industry 'often subject to declining average selling prices' and warns that competitors 'may utilize pricing strategies, including offering products at prices at or below cost, that we may be unable to competitively match'. Gross margin swung from 7.1% (FY2023) to 16.1% (FY2024) to 30.1% (FY2025) on the cycle rather than on sustained pricing, and FY2025 Consumer ASP per gigabyte still fell 7% 'due to pricing pressure'. | strong FY2025 operating margin hit a record 49% (operating profit +101% YoY) as HBM revenue more than doubled — unusually strong pricing power for a memory maker, per SK hynix's FY25 release. | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| Summary | SanDisk sells largely interchangeable NAND product into a five-rival commodity market, so its defensible edge is narrow and concentrated in intangibles: the SanDisk consumer brand and retail distribution (Consumer was $2,268M of $7,355M FY2025 revenue) plus roughly 7,900 granted patents. It owns no flash fab of its own; the 10-K says substantially all of its flash memory wafers come from Flash Ventures, its 49.9% JV with Kioxia, whose fixed costs it must fund at about half regardless of the output it takes. That structure caps both the moat and the downside cushion: gross margin ran 7.1% in FY2023, 16.1% in FY2024 and 30.1% in FY2025 as the flash cycle turned. | SK hynix's durable advantage rests on an HBM process-and-packaging lead: it held roughly 62% of the HBM market in Q2 2025 (Counterpoint) as NVIDIA's key HBM partner, and delivered industry-first HBM4 mass production. That lead drove record FY2025 results with a 49% operating margin, though rivals are qualifying competing HBM parts. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| Chain position | Merchant NAND/SSD supplier with no wholly owned fab: substantially all flash wafers come from Flash Ventures, its 49.9% JV with Kioxia across seven Japanese fabs, with an eighth due to start in calendar 2025. | Primary supplier of HBM (high-bandwidth memory) stacked onto NVIDIA's AI accelerators; HBM represented roughly 77% of Q2 2025 revenue. | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.01 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.24 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |